Opdivo wins Japanese approval in two further indications

25 November 2021

Japanese drugmaker Ono Pharmaceutical (TYO: 4528) and its partner Bristol Myers Squibb (NYSE: BMY) have announced the approval for the use of Opdivo (nivolumab) in two new indications in Japan.

The anti-PD-1 monoclonal antibody has been approved as a first-line treatment of unresectable advanced or recurrent gastric cancer in combination with chemotherapy, and as an adjuvant treatment of esophageal cancer.

This carries on the march of Opdivo in Japan, where it has become an important treatment option across multiple cancers since the approval for the treatment of melanoma in July 2014.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK